Pemigatinib
Pemigatinib
Definition
An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.
Also known as 2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-, INCB 054828, INCB-054828, INCB054828, Pemazyre, PEMIGATINIB — per NCIT
Also identified as
- ATC L01EN02 per RXNORM
- NCIT NCIT:C121553 per NCIT
- SCTID 871699001 per RXNORM
- SCTID 871709004 per RXNORM
- UNII Y6BX7BL23K per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Cholangiocarcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Alimentary part of gastrointestinal system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Bile ducts | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Biliary system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.